Temporal Muscle Thickness is an Independent Prognostic Biomarker in Patients with Glioma: Analysis of 261 Cases

References

• OstromQT, GittlemanH, LiaoP, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncology. 2017;19(suppl_5):v1–v88. doi:10.1093/neuonc/nox15829117289
   PubMed Web of Science ®Google Scholar
• StuppR, MasonWP, van den BentMJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
   PubMed Web of Science ®Google Scholar
• SunX, TurcanS. From laboratory studies to clinical trials: temozolomide use in IDH-mutant gliomas. Cells. 2021;10(5):1225. doi:10.3390/cells1005122534067729
   PubMed Web of Science ®Google Scholar
• StuppR, HegiME, MasonWP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. doi:10.1016/s1470-2045(09)70025-719269895
   PubMed Web of Science ®Google Scholar
• van den BentMJ, SmitsM, KrosJM, ChangSM. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol. 2017;35(21):2394–2401. doi:10.1200/jco.2017.72.673728640702
   PubMed Web of Science ®Google Scholar
• FurtnerJ, GenbruggeE, GorliaT, et al. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro-Oncology. 2019;21(12):4709–4717. doi:10.1093/neuonc/noz131
   Web of Science ®Google Scholar
• ZhaoYY, ChenSH, HaoZ, ZhuHX, XingZL, LiMH. A nomogram for predicting individual prognosis of patients with low-grade glioma. World Neurosurg. 2019;130:e605–e12. doi:10.1016/j.wneu.2019.06.16931319188
   PubMed Web of Science ®Google Scholar
• YangY, YaoM, LongS, et al. Prognostic nomograms for primary high-grade glioma patients in adult: a retrospective study based on the SEER database. Biomed Res Int. 2020;2020:1346340. doi:10.1155/2020/134634032775408
   PubMed Web of Science ®Google Scholar
• Gomes Dos SantosA, de CarvalhoRF, de MoraisA, et al. Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: a systematic review. Crit Rev Oncol Hematol. 2021;163:103372. doi:10.1016/j.critrevonc.2021.10337234062242
   PubMed Web of Science ®Google Scholar
• RigamontiA, ImbesiF, SilvaniA, et al. Prognostic nutritional index as a prognostic marker in glioblastoma: data from a cohort of 282 Italian patients. J Neurol Sci. 2019;400:175–179. doi:10.1016/j.jns.2019.04.00230974322
   PubMed Web of Science ®Google Scholar
• WangPF, MengZ, SongHW, et al. Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival. Front Pharmacol. 2018;9:886. doi:10.3389/fphar.2018.0088630154718
   PubMed Web of Science ®Google Scholar
• LinharesP, CarvalhoB, VazR, CostaBM. Glioblastoma: Is there any blood biomarker with true clinical relevance?Int J Mol Sci. 2020;21(16):5809. doi:10.3390/ijms21165809
   PubMed Web of Science ®Google Scholar
• AppinCL, BratDJ. Biomarker-driven diagnosis of diffuse gliomas. Mol Aspects Med. 2015;45:87–96. doi:10.1016/j.mam.2015.05.00226004297
   PubMed Web of Science ®Google Scholar
• ShacharSS, WilliamsGR, MussHB, NishijimaTF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67. doi:10.1016/j.ejca.2015.12.03026882087
   PubMed Web of Science ®Google Scholar
• FurtnerJ, NenningKH, RoetzerT, et al. Evaluation of the temporal muscle thickness as an independent prognostic biomarker in patients with primary central nervous system lymphoma. Cancers. 2021;13(3):566. doi:10.3390/cancers1303056633540564
   PubMed Web of Science ®Google Scholar
• OlsonB, EdwardsJ, StoneL, et al. Association of sarcopenia with oncologic outcomes of primary surgery or definitive radiotherapy among patients with localized oropharyngeal squamous cell carcinoma. JAMA Otolaryngol. 2020;146(8):1–9. doi:10.1001/jamaoto.2020.1154
   Google Scholar
• LeitnerJ, PelsterS, SchöpfV, et al. High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. PLoS One. 2018;13(11):e0207849. doi:10.1371/journal.pone.020784930496307
   PubMed Web of Science ®Google Scholar
• FurtnerJ, BerghoffAS, SchöpfV, et al. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. J Neurooncol. 2018;140(1):173–178. doi:10.1007/s11060-018-2948-830008154
   PubMed Web of Science ®Google Scholar
• ChukwuekeUN, WenPY. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019;8(1):Cns28. doi:10.2217/cns-2018-000730806082
   PubMedGoogle Scholar
• ChargiN, BrilSI, Emmelot-VonkMH, de BreeR. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Otorhinolaryngol. 2019;276(5):1475–1486. doi:10.1007/s00405-019-05361-430830300
   PubMed Web of Science ®Google Scholar
• YangM, ShenY, TanL, LiW. Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest. 2019;156(1):101–111. doi:10.1016/j.chest.2019.04.11531128115
   PubMed Web of Science ®Google Scholar
• FurtnerJ, BerghoffAS, AlbtoushOM, et al. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. Eur Radiol. 2017;27(8):3167–3173. doi:10.1007/s00330-016-4707-628050694
   PubMed Web of Science ®Google Scholar
• KatsukiM, YamamotoY, UchiyamaT, WadaN, KakizawaY. Clinical characteristics of aneurysmal subarachnoid hemorrhage in the elderly over 75; would temporal muscle be a potential prognostic factor as an indicator of sarcopenia?Clin Neurol Neurosurg. 2019;186:105535. doi:10.1016/j.clineuro.2019.10553531569058
   PubMed Web of Science ®Google Scholar
• AnG, AhnS, ParkJS, JeunSS, HongYK. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma. J Cancer Res Clin Oncol. 2021;147(3):901–909. doi:10.1007/s00432-020-03386-532929611
   PubMed Web of Science ®Google Scholar
• MugliaR, SimonelliM, PessinaF, et al. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. Eur Radiol. 2020;31(6):4079–4086.. doi:10.1007/s00330-020-07471-833201284
   PubMed Web of Science ®Google Scholar
• WangDP, KangK, LinQ, HaiJ. Prognostic significance of preoperative systemic cellular inflammatory markers in gliomas: a systematic review and meta-analysis. Clin Transl Sci. 2020;13(1):179–188. doi:10.1111/cts.1270031550075
   PubMed Web of Science ®Google Scholar
• SantilliV, BernettiA, MangoneM, PaoloniM. Clinical definition of sarcopenia. Clin Cases Miner Bone Metab. 2014;11(3):177–180.25568649
   PubMedGoogle Scholar
• BauerJ, MorleyJE, ScholsA, et al. Sarcopenia: a time for action. An SCWD position paper. J Cachexia Sarcopenia Muscle. 2019;10(5):956–961. doi:10.1002/jcsm.1248331523937
   PubMed Web of Science ®Google Scholar
• FaronA, PieperCC, SchmeelFC, et al. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases. Eur Radiol. 2019;29(9):4709–4717. doi:10.1007/s00330-018-5976-z30689036
   PubMed Web of Science ®Google Scholar
• LiguoriI, RussoG, AranL, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. Clin Interv Aging. 2018;13:913–927. doi:10.2147/cia.S14923229785098
   PubMed Web of Science ®Google Scholar
• Yesil CinkirH, ColakogluEH. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?Asia Pac J Clin Oncol. 2020;16(5):e223–e227. doi:10.1111/ajco.1336932762134
   PubMed Web of Science ®Google Scholar
• ZhengSH, HuangJL, ChenM, WangBL, OuQS, HuangSY. Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study. J Neurosurg. 2018;129(3):583–592. doi:10.3171/2017.3.Jns16164829099300
   PubMed Web of Science ®Google Scholar
• LiuJ, TianX, WangY, KangX, SongW. Soluble cytotoxic T-lymphocyte–associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma. BMC Immunol. 2021;22(1):33. doi:10.1186/s12865-021-00422-y34006227
   PubMed Web of Science ®Google Scholar
• ZhaoS, WangM, YangZ, et al. Comparison between child-pugh score and albumin-bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Trans Med. 2020;8(8):539. doi:10.21037/atm.2020.02.85
   PubMed Web of Science ®Google Scholar
• HuangF, GaoJ. Modified Child-Pugh grade vs albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy. World J Gastroenterol. 2020;26(7):749–758. doi:10.3748/wjg.v26.i7.74932116422
   PubMed Web of Science ®Google Scholar
• HeQ, LiL, RenQ. The prognostic value of preoperative systemic inflammatory response index (siri) in patients with high-grade glioma and the establishment of a nomogram. Front Oncol. 2021;11:671811. doi:10.3389/fonc.2021.67181134055639
   PubMed Web of Science ®Google Scholar
• HochbergFH, AtaiNA, GondaD, et al. Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Rev Mol Diagn. 2014;14(4):439–452. doi:10.1586/14737159.2014.90520224746164
   PubMed Web of Science ®Google Scholar